CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat

The nitroxyl (HNO) prodrug, CXL-1020, induces vasorelaxation and improves cardiac function in canine models and patients with systolic heart failure (HF). HNO's unique mechanism of action may be applicable to a broader subset of cardiac patients. This study investigated the load-independent saf...

Full description

Bibliographic Details
Main Authors: Steve R. Roof, Yukie Ueyama, Reza Mazhari, Robert L. Hamlin, J. Craig Hartman, Mark T. Ziolo, John E. Reardon, Carlos L. del Rio
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-11-01
Series:Frontiers in Physiology
Subjects:
nitroxyl
CXL-1020
cardiac diastolic dysfunction
cardiovascular therapeutic
Online Access:http://journal.frontiersin.org/article/10.3389/fphys.2017.00894/full

Internet

http://journal.frontiersin.org/article/10.3389/fphys.2017.00894/full

Similar Items